BioAtla

BioAtla is a clinical-stage biopharmaceutical company developing novel antibody and cell-based therapeutics for solid tumors using its proprietary Conditionally Active Biologics (CAB) platform, which exploits the tumor microenvironment to improve therapeutic index. Lead programs include mecbotamab vedotin (BA3011), a CAB-AXL antibody-drug conjugate (ADC) in clinical development for undifferentiated pleomorphic sarcoma and non-small cell lung cancer, and ozuriftamab vedotin (CAB-ROR2-ADC), targeting ROR2-expressing tumors. The company initiated a strategic review in March 2026; in August 2026 the Nasdaq Listing Council affirmed a delisting determination and the common stock is expected to transition to OTC Markets trading effective August 31, 2026.